[ad_1]
Richter Gedeon Plc. It announced Thursday that it has entered into an asset purchase agreement with Johnson & Johnson’s wholly-owned subsidiary, Janssen, to purchase its Evra-brand contraceptive patch. This means that from here on Richter will be able to sell Evra in markets outside the United States. According to the announcement, the purchase price is 263.5 million dollars.
Janssen will provide transitional support to facilitate the transfer of marketing authorizations outside of the United States.
“This agreement further strengthens Richter’s global role in gynecology and is an important strategic step forward for our company. In addition to existing drug delivery methods such as oral contraception, emergency contraception and intrauterine devices, this time the patch will be aligned, allowing Richter to offer the broadest range of family planning tools for women. ” .
Said Erik Bogsch, president of Richter.
Evra is a contraceptive for women approved once a week. It is the first approved transdermal hormonal patch, as well as the first non-invasive form of contraception that provides 99 percent effectiveness when used correctly.
Evra is a square patch that is applied to the lower abdomen, buttocks, upper body, or outer arm. A patch can be worn for seven days, after which it must be changed for three weeks. The fourth week is drug-free, as with oral contraceptives.
(Cover image: Evra brand contraceptive patch. Photo: Bsip / Getty Images Hungary)
[ad_2]
